Literature DB >> 12609964

Severe skin reaction to imatinib in a case of Philadelphia-positive acute lymphoblastic leukemia.

Blanca Sanchez-Gonzalez, Jose C Pascual-Ramirez, Pascual Fernandez-Abellan, Isabel Belinchon-Romero, Concepcion Rivas, Gloria Vegara-Aguilera.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2003        PMID： 12609964     DOI： 10.1182/blood-2002-12-3696

Source DB:  PubMed          Journal:  Blood        ISSN： 0006-4971            Impact factor:   22.113


× No keyword cloud information.
  7 in total

1.  Imatinib-induced Stevens-Johnsons syndrome.

Authors:  Praveen Jha; D Himanshu; Nirdesh Jain; Ajay Kumar Singh
Journal:  BMJ Case Rep       Date:  2013-01-23

Review 2.  Imatinib: in relapsed or refractory Philadelphia chromosome-positive acute lymphoblastic leukaemia.

Authors:  Sarah A Cross; Katherine A Lyseng-Williamson
Journal:  Drugs       Date:  2007       Impact factor: 9.546

3.  Lenalidomide cutaneous adverse event: a case of Stevens-Johnson syndrome (SJS) in a primary plasma cell leukaemia patient treated with lenalidomide and dexamethasone.

Authors:  A Siniscalchi; A Tendas; L Morino; T Dentamaro; A De Bellis; A Perrotti; P de Fabritiis; P Musto; T Caravita
Journal:  Support Care Cancer       Date:  2012-05-05       Impact factor: 3.603

Review 4.  Potentially life‑threatening severe cutaneous adverse reactions associated with tyrosine kinase inhibitors (Review).

Authors:  Emily L Coleman; Brianna Olamiju; Jonathan S Leventhal
Journal:  Oncol Rep       Date:  2020-12-24       Impact factor: 3.906

5.  Lichenoid drug eruption due to imatinib mesylate.

Authors:  Anuradha Bhatia; Bimal Kanish; Paulina Chaudhary
Journal:  Int J Appl Basic Med Res       Date:  2015 Jan-Apr

Review 6.  Severe cutaneous adverse reactions induced by targeted anticancer therapies and immunotherapies.

Authors:  Chun-Bing Chen; Ming-Ying Wu; Chau Yee Ng; Chun-Wei Lu; Jennifer Wu; Pei-Han Kao; Chan-Keng Yang; Meng-Ting Peng; Chen-Yang Huang; Wen-Cheng Chang; Rosaline Chung-Yee Hui; Chih-Hsun Yang; Shun-Fa Yang; Wen-Hung Chung; Shih-Chi Su
Journal:  Cancer Manag Res       Date:  2018-05-17       Impact factor: 3.989

7.  Therapeutic options for chronic myeloid leukemia: focus on imatinib (Glivec, Gleevectrade mark).

Authors:  Martin Henkes; Heiko van der Kuip; Walter E Aulitzky
Journal:  Ther Clin Risk Manag       Date:  2008-02       Impact factor: 2.423
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.